X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Crofelemer is a plant-based drug extracted & purified from the red bark sap. It is being developed for relief and treatment of moderate-to-severe diarrhea, with or without concomitant antimicrobial therapy from bacterial, viral & parasitic infections including Vibrio cholerae.
Lead Product(s): Crofelemer
Therapeutic Area: Gastroenterology Product Name: Undisclosed
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 12, 2024
Details:
Mytesi (crofelemer) is a CFTR/CaCC inhibitor small molecule drug administered orally as a delayed release tablet, for prophylaxis of diarrhea in cancer patients.
Lead Product(s): Crofelemer
Therapeutic Area: Gastroenterology Product Name: Mytesi
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 11, 2023
Details:
Under the agreement, Napo grants Quadri Pharma exclusive promotional, commercialization, and distribution rights for a powder formulation of Mytesi (crofelemer), the only oral FDA-approved prescription drug under botanical guidance, for oral solution.
Lead Product(s): Crofelemer
Therapeutic Area: Gastroenterology Product Name: Mytesi
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Quadri Pharmaceuticals
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement November 02, 2023
Details:
Mytesi (crofelemer) powder for oral solution inhibits both cAMP-stimulated CFTR chloride ion channel and the CaCC at the luminal membrane of enterocytes, which being investigated for the treatment of microvillus inclusion disease.
Lead Product(s): Crofelemer
Therapeutic Area: Genetic Disease Product Name: Mytesi
Highest Development Status: IND EnablingProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 09, 2023
Details:
Mytesi, only oral plant-based prescription medicine approved under FDA Botanical Guidance, is a novel, first-in-class anti-secretory agent which has a basic normalizing effect locally on the gut, and this mechanism of action has the potential to benefit multiple disorders.
Lead Product(s): Crofelemer
Therapeutic Area: Gastroenterology Product Name: Mytesi
Highest Development Status: UndisclosedProduct Type: Small molecule
Recipient: Jaguar Health
Deal Size: $5.0 million Upfront Cash: Undisclosed
Deal Type: Agreement March 09, 2021
Details:
Oasis agreed to purchase additional accounts receivable of the Company related to the sales of the Company's Mytesi® drug product to Cardinal Health for the period of August 11, 2020 through September 3, 2020.
Lead Product(s): Crofelemer
Therapeutic Area: Gastroenterology Product Name: Mytesi
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Oasis Capital
Deal Size: $2.3 million Upfront Cash: Undisclosed
Deal Type: Agreement September 10, 2020
Details:
Under the the license, Jaguar has to initiate Phase 2 study of NP-500 under an investigational new drug application with the U.S. FDA or an IND-equivalent dossier within six months of April 15, 2020.
Lead Product(s): NP-500
Therapeutic Area: Endocrinology Product Name: Undisclosed
Highest Development Status: Phase IProduct Type: Undisclosed
Partner/Sponsor/Collaborator: Atlas Sciences
Deal Size: $1.5 million Upfront Cash: Undisclosed
Deal Type: Licensing Agreement April 16, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
